索拉非尼诱导肝癌细胞凋亡信号通路的研究进展

张朝亚; 赵相轩; 卢再鸣; 郭启勇

doi:10.3969/j.issn.1001-5256.2016.04.048

索拉非尼诱导肝癌细胞凋亡信号通路的研究进展

DOI: 10.3969/j.issn.1001-5256.2016.04.048

中国医科大学附属盛京医院放射科

基金项目:

国家自然科学基金(31240025,31371425)；辽宁省自然科学基金(2013023056)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2405
- HTML全文浏览量: 13
- PDF下载量: 500
- 被引次数: 0
出版历程
- 出版日期: 2016-04-20

Research advances in sorafenib- induced apoptotic signaling pathways in liver cancer cells

Department of Radiology, China Medical University Shengjing Hospital

Research funding:

摘要

摘要:
索拉非尼是治疗进展期原发性肝癌的多靶点抑制剂,可以有效提高进展期原发性肝癌患者疾病无进展生存期和总体生存期,其在肝癌靶向治疗中的应用已成为目前的研究热点,主要的作用靶点或信号通路有Raf/Mek/Erk、Jak/Stat、PI3K/Akt/m TOR、血管内皮生长因子受体和血小板衍生生长因子、STAT、微小RNA、Wnt/β-catenin、自噬性溶酶体以及肿瘤相关蛋白,通过这些靶点可调控肝癌细胞的增殖、分化、转移以及凋亡。主要就索拉非尼作用的这些靶点或信号通路的研究现状进行综述,为索拉非尼进一步临床科学研究提供有益线索。
- 肝肿瘤 /
- 索拉非尼 /
- 细胞凋亡 /
- 信号传导 /
- 综述
Abstract:
Currently,sorafenib is the multi- target inhibitor for the treatment of advanced primary liver cancer,and can effectively prolong the progression- free survival and overall survival in patients with advanced primary liver cancer. The application of sorafenib in the targeted therapy for liver cancer has become a hot topic. Major targets or signaling pathways include Raf / Mek / Erk,Jak / Stat,PI3 K / Akt / m TOR,VEGFR and PDGFR,STAT,microRNA,Wnt / β- catenin,autolysosome,and tumor- related proteins,and sorafenib can regulate the proliferation,differentiation,metastasis,and apoptosis of liver cancer cells through these targets. This article reviews the current research on the action of sorafenib on these targets or signaling pathways to provide useful references for further clinical research on sorafenib.
- liver neoplasms /
- sorafenib /
- apoptosis /
- signal transduction /
- review

HTML全文

参考文献(42)

[1]HARNOIS DM.Hepatitis C virus infection and the rising incidence of hepatocellular carcinoma[J].Mayo Clin Proc,2012,87(1):7-8.

[2]HWANG YH,CHOI JY,KIM S,et al.Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma[J].Hepatol Res,2004,29(2):113-121.

[3]WILHELM SM,CARTER C,TANG L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Hepatol Res,2004,64(19):7099-7109.

[4]LIU L,CAO Y,CHEN C,et al.Sorafenib blocks the RAF/MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J].Cancer Res,2006,66(24):11851-11858.

[5]MAO WF,SHAO MH,GAO PT,et al.The important roles of RET,VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib[J].Acta Pharmacol Sin,2012,33(10):1311-1318.

[6]CHEN D,ZHAO P,LI SQ,et al.Prognostic impact of p ERK in advanced hepatocellular carcinoma patients treated with sorafenib[J].Eur J Surg Oncol,2013,39(9):974-980.

[7]FASOLO A,SESSA C.Targeting mT OR pathways in human malignancies[J].Curr Pharm Des,2012,18(19):2766-2777.

[8]GEDALY R,ANGULO P,HUNDLEY J,et al.PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mT OR pathways[J].Anticancer Res,2010,30(12):4951-4958.

[9]CHEN KF,CHEN HL,TAI WT,et al.Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells[J].J Pharmacol Exp Ther,2011,337(1):155-161.

[10]ZHANG CZ,WANG XD,WANG HW,et al.Sorafenib inhibits liver cancer growth by decreasing mT OR,AKT,and PI3K expression[J].J BUON,2015,20(1):218-222.

[11]GALUPPO R,RAMAIAH D,PONTE OM,et al.Molecular therapies in hepatocellular carcinoma:what can we target?[J].Dig Dis Sci,2014,59(8):1688-1697.

[12]LLOVET JM.Focal gains of VEGFA:candidate predictors of sorafenib response in hepatocellular carcinoma[J].Cancer Cell,2014,25(5):560-562..

[13]CHU JS,GE FJ,ZHANG B,et al.Expression and prognostic value of VEGFR-2,PDGFR-beta,and c-Met in advanced hepatocellular carcinoma[J].J Exp Clin Cancer Res,2013,32:16.

[14]MORGILLO F,MARTINELLI E,TROIANI T,et al.Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors[J].PLoSOne,2011,6(12):e28841.

[15]ERBER R,THURNHER A,KATSEN AD,et al.Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms[J].Faseb J,2004,18(2):338-340.

[16]HE G,KARIN M.NF-kappaB and STAT3-key players in liver inflammation and cancer[J].Cell Res,2011,21(1):159-168.

[17]ZHANG B,ZHONG DW,WANG QW,et al.Study on correlation of JAK/STAT signal pathway with progression and prognosis in hepatocellular carcinoma[J].Chin J Cell Immunol,2010,26(4):368-370,373.(in Chinese)张斌,钟德玝,王群伟,等.JAK/STAT信号通路与肝细胞性肝癌的肿瘤进展和预后的相关性研究[J].细胞与分子免疫学杂志,2010,26(4):368-370,373.

[18]WU WY,LI J,WU ZS,et al.STAT3 activation in monocytes accelerates liver cancer progression[J].BMC Cancer,2011,11(12):506.

[19]TAI WT,CHENG AL,SHIAU CW,et al.Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma[J].J Hepatol,2011,55(5):1041-1048.

[20]GU FM,LI QL,GAO Q,et al.Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3[J].World JGastroenterol,2011,17(34):3922-3932.

[21]KONG J,KONG F,GAO J,et al.YC-1 enhances the antitumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3(STAT3)in hepatocellular carcinoma[J].Mol Cancer,2014,13:7.

[22]BRACONI C,HENRY JC,KOGURE T,et al.The role of microR-NAs in human liver cancers[J].Semin Oncol,2011,38(6):752-763.

[23]LIN K,CIDAN WJ,CHANG ZH,et al.Clinical value of circulating microRNA in hepatic,biliary and pancreatic carcinomas[J].JClin Hepatol,2015,31(5):790-795.(in Chinese)林坤,次旦旺久,畅智慧,等.循环microRNAs在肝胆胰肿瘤发生发展中的作用[J].临床肝胆病杂志,2015,31(5):790-795.

[24]CHENG BX,FANG X,ZHU CL,et al.Altered expression levels of miRNAs in serum of patients with hepatocellular carcinoma in the treatment of sorafenib[J].China Med Herald,2014,11(9):41-44.(in Chinese)成炳祥,方煊,朱承良,等.索拉非尼对肝癌患者血清中肿瘤相关miRNAs的影响[J].中国医药导报,2014,11(9):41-44.

[25]HUANG S,HE X.The role of microRNAs in liver cancer progression[J].Br J Cancer,2011,104(2):235-240.

[26]BAI S,NASSER MW,WANG B,et al.MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib[J].J Biol Chem,2009,284(46):32015-32027.

[27]SALVI A,CONDE I,ABENI E,et al.Effects of miR-193a and sorafenib on hepatocellular carcinoma cells[J].Mol Cancer,2013,12:162.

[28]VAIRA V,RONCALLI M,CARNAGHI C,et al.MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma[J].Liver Int,2015,35(3):1077-1086.

[29]BLAGODATSKI A,POTERYAEV D,KATANAEV VL.Targeting the Wnt pathways for therapies[J].Mol Cell Ther,2014,2(1):28.

[30]CUI J,ZHOU X,LIU Y,et al.Wnt signaling in hepatocellular carcinoma:analysis of mutation and expression of beta-catenin,T-cell factor-4 and glycogen synthase kinase 3-beta genes[J].J Gastroenterol Hepatol,2003,18(3):280-287.

[31]WEI Y,SHEN N,WANG Z,et al.Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/beta-catenin signaling[J].Mol Cell Biochem,2013,381(1-2):139-144.

[32]LACHENMAYER A,ALSINET C,SAVIC R,et al.Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib[J].Clin Cancer Res,2012,18(18):4997-5007.

[33]TANG Q,BU WH,WANG DD,et al.Advance research on interaction between autophagy and apoptosis and its influence in development of tumors[J].J Jilin Univ:Med Edit,2015,41(6):1303-1306.(in Chinese)唐琪,布文奂,王丹丹,等.自噬与凋亡的相互作用及其对肿瘤发展过程影响的研究进展[J].吉林大学学报:医学版,2015,41(6):1303-1306.

[34]FISCHER TD,WANG JH,VLADA A,et al.Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib[J].World J Hepatol,2014,6(10):752-758.

[35]SHIMIZU S,TAKEHARA T,HIKITA H,et al.Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma[J].Int J Cancer,2012,131(3):548-557.

[36]WANG K,LIN B.Inhibitor of apoptosis proteins(IAPs)as regulatory factors of hepatic apoptosis[J].Cell Signal,2013,25(10):1970-1980.

[37]ZHAO X,OGUNWOBI OO,LIU C.Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells[J].PLoS One,2011,6(8):e21980.

[38]HIKITA H,TAKEHARA T,SHIMIZU S,et al.The Bcl-xL inhibitor,ABT-737,efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib[J].Hepatology,2010,52(4):1310-1321.

[39]ZHU H,CHEN XP,ZHANG WG,et al.Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma[J].World J Gastroenterol,2005,11(25):3855-3859.

[40]LI XF,GONG RY,WANG M,et al.Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis[J].Biochem Biophys Res Commun,2012,418(3):531-536.

[41]LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.

[42]CHENG AL,KANG YK,CHEN Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.

施引文献

资源附件(0)

访问统计